David Chang Biography and Net Worth

Chief Medical Officer of Cabaletta Bio

Dr. Chang joined Cabaletta in June 2019 as Chief Medical Officer. Previously, he was Senior Vice President and Head, Inflammation, Autoimmunity & Neuroscience, or IA&NS, Global Medicines Development at AstraZeneca Pharmaceuticals LP, where he oversaw development projects of both biologics and small molecules in a variety of indications and led the late-stage clinical development organization for IA&NS. Prior to AstraZeneca, Dr. Chang served in various positions at GlaxoSmithKline plc, including VP and Head, Immuno-Inflammation, Clinical Development. While at AstraZeneca and GlaxoSmithKline, he provided leadership in driving the clinical development and registration of the only two products approved for systemic lupus erythematosus in the US in over 60 years. From 1997-2022, Dr. Chang was a faculty member in the Division of Rheumatology at the Perelman School of Medicine at the University of Pennsylvania. He received his M.D. from New York University School of Medicine, his M.P.H. from Emory University, and his B.S. from Yale University. Dr. Chang completed his internship and residency in internal medicine at the New York Hospital—Cornell University Medical Center and fellowship in Rheumatology at the Hospital for Special Surgery—Cornell University Medical Center. He is a Fellow of the American College of Rheumatology.

What is David J. Chang's net worth?: The estimated net worth of David J. Chang is at least $31.37 thousand as of January 21st, 2026. Dr. Chang owns 8,800 shares of Cabaletta Bio stock worth more than $31,372 as of May 4th. This net worth evaluation does not reflect any other assets that Dr. Chang may own. Learn More about David J. Chang's net worth.
How do I contact David J. Chang?: The corporate mailing address for Dr. Chang and other Cabaletta Bio executives is 2929 ARCH STREET SUITE 600, PHILADELPHIA PA, 19104. Cabaletta Bio can also be reached via phone at 267-759-3100 and via email at [email protected]. Learn More on David J. Chang's contact information.
Has David J. Chang been buying or selling shares of Cabaletta Bio?: David J. Chang has not been actively trading shares of Cabaletta Bio during the last quarter. Most recently, on Wednesday, January 21st, David J. Chang bought 8,800 shares of Cabaletta Bio stock. The stock was acquired at an average cost of $2.26 per share, with a total value of $19,888.00. Following the completion of the transaction, the insider now directly owns 8,800 shares of the company's stock, valued at $19,888. Learn More on David J. Chang's trading history.
Are insiders buying or selling shares of Cabaletta Bio?: In the last twelve months, Cabaletta Bio insiders bought shares 7 times. They purchased a total of 127,668 shares worth more than $286,210.51. The most recent insider tranaction occured on January, 21st when insider David J Chang bought 8,800 shares worth more than $19,888.00. Insiders at Cabaletta Bio own 11.3% of the company. Learn More about insider trades at Cabaletta Bio.
Information on this page was last updated on 1/21/2026.

David J. Chang Insider Trading History at Cabaletta Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/21/2026	Buy	8,800	$2.26	$19,888.00	8,800

David J. Chang Buying and Selling Activity at Cabaletta Bio

Cabaletta Bio Company Overview

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Today's Range

Now: $4.01

$3.16

$4.00

50 Day Range

MA: $3.08

$2.47

$3.52

2 Week Range

Now: $4.01

$1.11

$4.00

Volume

22,299,369 shs

Average Volume

2,968,043 shs

Market Capitalization

$446.73 million

P/E Ratio

N/A

Dividend Yield